Goldman Sachs Group Inc Acadia Pharmaceuticals Inc Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,178,770 shares of ACAD stock, worth $49.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,178,770
Previous 2,358,370
7.62%
Holding current value
$49.5 Million
Previous $39.2 Million
7.62%
% of portfolio
0.01%
Previous 0.01%
Shares
22 transactions
Others Institutions Holding ACAD
# of Institutions
351Shares Held
165MCall Options Held
1.77MPut Options Held
307K-
Baker Bros. Advisors LP New York, NY42.9MShares$974 Million8.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$345 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$274 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.54MShares$194 Million2.32% of portfolio
-
State Street Corp Boston, MA6.99MShares$159 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.68B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...